Abstract: The present invention relates generally to a magnetic catalyst for wet oxidation of organic waste and the preparation method thereof. According to the present invention, after the raw materials are dissolved and mixed in water, the pH value is adjusted for producing precipitates. Then after heating, filtering, drying, grinding, sifting, and calcinations are performed, the given magnetic catalyst can be reused without losing its activity. In addition, during treating organic waste by using wet oxidation method, no secondary waste is produced. Besides, the magnetic catalyst can be recycled by magnetic devices, making it excellent in terms of performance and convenience.

Abstract: The present invention relates generally to a magnetic catalyst for wet oxidation of organic waste and the preparation method thereof. According to the present invention, after the raw materials are dissolved and mixed in water, the pH value is adjusted for producing precipitates. Then after heating, filtering, drying, grinding, sifting, and calcinations are performed, the given magnetic catalyst can be reused without losing its activity. In addition, during treating organic waste by using wet oxidation method, no secondary waste is produced. Besides, the magnetic catalyst can be recycled by magnetic devices, making it excellent in terms of performance and convenience.

Abstract: This invention provides a process for producing a radioactive arsenic-containing compound, comprising the steps of: (i) subjecting an arsenic-containing compound to a neutron irradiation treatment, said arsenic-containing compound being selected from a group consisting of As2O3, As2S3, As2S2, and a combination thereof, such that the arsenic element contained in the arsenic-containing compound is converted to a radioactive arsenic isotope; and (ii) recovering the resultant product from step (i). This invention also provides a pharmaceutical composition comprising a therapeutically effective amount of the radioactive arsenic-containing compound and a pharmaceutically acceptable carrier. The pharmaceutical composition can be used in the treatment of tumors/cancers such as hematological malignancies and solid tumors.

Abstract: This invention provides a process for producing a radioactive arsenic-containing compound, comprising the steps of: (i) subjecting an arsenic-containing compound to a neutron irradiation treatment, said arsenic-containing compound being selected from a group consisting of As2O3, As2S3, As2S2, and a combination thereof, such that the arsenic element contained in the arsenic-containing compound is converted to a radioactive arsenic isotope; and (ii) recovering the resultant product from step (i). This invention also provides a pharmaceutical composition comprising a therapeutically effective amount of the radioactive arsenic-containing compound and a pharmaceutically acceptable carrier. The pharmaceutical composition can be used in the treatment of tumors/cancers such as hematological malignancies and solid tumors.

Abstract: This invention provides a process for producing a radioactive arsenic-containing compound, comprising the steps of: (i) subjecting an arsenic-containing compound to a neutron irradiation treatment, said arsenic-containing compound being selected from a group consisting of As2O3, As2S3, AS2S2, and a combination thereof, such that the arsenic element contained in the arsenic-containing compound is converted to a radioactive arsenic isotope; and (ii) recovering the resultant product from step (i).